Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, and other medical equipment. In-home sleep testing provides in home sleep apnea testing services. Healthcare staffing provides healthcare staffing and recruitment services. The Company provides home medical equipment services through its interest in East Alabama HomeMed, LLC (HomeMed).


NDAQ:VMD - Post by User

Comment by donmayneon Feb 19, 2022 1:44pm
151 Views
Post# 34445071

RE:RE:RE:RE:APR was acquired for 7x adj. EBITDA, VMD at 4.5x adj. EBITDA

RE:RE:RE:RE:APR was acquired for 7x adj. EBITDA, VMD at 4.5x adj. EBITDASorry Longterm...I thought the conversation was about growth rates so I posted the most recent public observation from Casey Hoyt and commented that it would have to be adjusted downwards for the subsequent Omicron surge.  I felt that was the same subject of growth rates that you were speaking to.  

Since posting my comments, I have now read Stockfy's vitriolic attack on an earlier post about the sales by the the 13G filers. I will place Stockfy on ignore and so I won't inadvertently respond to any of his threads. I should have placed him on ignore earlier.

Reciprocally, I recommend he put me on ignore because objective comments on VieMed appear to be trigger warnings. 
<< Previous
Bullboard Posts
Next >>